


Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

Lorenzo Iovino ,¹ Laurel A Thur,¹ Sacha Gnjatic,² Aude Chapuis,^{1,3} Filippo Milano,^{1,3} Joshua A Hill^{1,3,4}

To cite: Iovino L, Thur LA, Gnjatic S, *et al.* Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. *Journal for ImmunoTherapy of Cancer* 2021;9:e002392. doi:10.1136/jitc-2021-002392

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jitc-2021-002392>).

FM and JAH contributed equally.

Accepted 15 April 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

²Medicine—Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

³Department of Medicine, University of Washington, Seattle, Washington, USA

⁴Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Correspondence to

Dr Joshua A Hill;
jahill3@fredhutch.org

ABSTRACT

COVID-19, the syndrome caused by the infection with SARS-CoV-2 coronavirus, is characterized, in its severe form, by interstitial diffuse pneumonitis and acute respiratory distress syndrome (ARDS). ARDS and systemic manifestations of COVID-19 are mainly due to an exaggerated immune response triggered by the viral infection. Cytokine release syndrome (CRS), an inflammatory syndrome characterized by elevated levels of circulating cytokines, and endothelial dysfunction are systemic manifestations of COVID-19. CRS is also an adverse event of immunotherapy (IMTX), the treatment of diseases using drugs, cells, and antibodies to stimulate or suppress the immune system. Graft-versus-host disease complications after an allogeneic stem cell transplant, toxicity after the infusion of chimeric antigen receptor-T cell therapy and monoclonal antibodies can all lead to CRS. It is hypothesized that anti-inflammatory drugs used for treatment of CRS in IMTX may be useful in reducing the mortality in COVID-19, whereas IMTX itself may help in ameliorating effects of SARS-CoV-2 infection. In this paper, we focused on the potential shared mechanisms and differences between COVID-19 and IMTX-related toxicities. We performed a systematic review of the clinical trials testing anti-inflammatory therapies and of the data published from prospective trials. Preliminary evidence suggests there might be a benefit in targeting the cytokines involved in the pathogenesis of COVID-19, especially by inhibiting the interleukin-6 pathway. Many other approaches based on novel drugs and cell therapies are currently under investigation and may lead to a reduction in hospitalization and mortality due to COVID-19.

INTRODUCTION

COVID-19 is a recent global public health catastrophe with substantial mortality and morbidity across the globe, caused by a novel beta coronavirus popularly known as SARS-CoV-2. SARS-CoV-2 has infected over 144 million people and caused approximately 3 million deaths globally, as of April 22, 2021.¹ The most prominent clinical manifestation of SARS-CoV-2 infection is acute respiratory distress syndrome (ARDS), which is also the primary cause of admission to intensive care units (ICUs). The viral replication and the

inflammatory events occurring within the lung are also thought to be critical for initiating many other extrapulmonary manifestations of COVID-19. SARS-CoV-2 RNA has been isolated from many organs and virtually all body fluids.² COVID-19 is often characterized by extrapulmonary involvement and signs of systemic inflammation, potentially leading to multiorgan failure and death.^{3,4} Interestingly, even after SARS-CoV-2 is controlled or cleared, patients remain in the hospital with inflammatory cytokines elevated and with elevated inflammatory cytokines and ongoing pulmonary damage.⁴

Immunotherapy (IMTX), defined here as any treatment using drugs, immune cells or antibodies to stimulate or suppress the immune system, is an emerging field in cancer therapy and infectious diseases.^{5,6} IMTX has produced impressive response rates in select patients with relapsed and refractory cancers; however, the toxicity profile of some of these approaches, such as chimeric antigen receptor-T cells (CAR-T cells), still represents a major limitation in their widespread use.⁷ A potentially fatal complication after IMTX is a condition referred to as ‘cytokine storm’ or ‘cytokine release syndrome’ (CRS), characterized by fever, hypotension, and respiratory failure in the presence of elevated cytokine and inflammatory markers.⁸ Many drugs have been successful in the treatment of CRS after IMTX, and many serologic markers are currently available to confirm the diagnosis and to monitor the therapeutic response. Systemic manifestations of COVID-19 and toxicity following IMTX may share similar pathophysiologic mechanisms. Therefore, the management of IMTX-related toxicities could be used as a paradigm for treating COVID-19 complications, and IMTX may have a potential role in the treatment of SARS-CoV-2 infection. In this review, we will compare these two clinical scenarios and

potential opportunities to leverage IMTX in treating patients with COVID-19.

Pathways of inflammation in COVID-19 infection and immunotherapy: parallels and differences

SARS-CoV-2 triggers severe inflammation initiated in the lung

SARS-CoV-2 recognizes the protein ACE2 expressed on the surface of the epithelial cells of the respiratory tract. The viral protein that mediates the adhesion and the recognition of ACE2 is the spike protein.⁹ After initial replication of the virus in the upper respiratory tract, viral replication can spread to the lower respiratory tract and cause pneumonia and ARDS. The majority of patients hospitalized for COVID-19 infections present with signs of pulmonary disease, including pneumonia and ARDS.¹⁰ Early signs and symptoms of lung involvement in SARS-CoV-2 infection are fever, tachypnea, low oxygen saturation, shortness of breath, and dry cough.¹¹ Other symptoms include dysphagia and coryza.¹² A substantial proportion of patients, ranging from 20% to 33%, require admission to an ICU.¹³ ARDS is the most frequent cause of admission to ICU and the major cause of mortality.¹⁴ Diffuse alveolar damage is the most common histologic finding; the blood–air interface is damaged, resulting in inflammation and thickening of the mucosa during the acute phases of infection. Furthermore, microvascular thrombosis and pleural effusion, two common post-mortem findings, contribute to the COVID-19 acute respiratory syndrome.¹⁵ Similar pathology is seen in patients receiving monoclonal antibodies (mAbs) targeting the tumor microenvironment by engaging the receptors PD-1 and CTLA4, the so called ‘checkpoint inhibitors’ (CPIs),¹⁶ to revert T cell anergy induced by cancer cells. A rare but significant side effect of CPI, especially nivolumab, is severe inflammatory interstitial pneumonitis showing clinical and radiologic features resembling lung involvement in COVID-19.¹⁷ The exact mechanism of CPI-related pneumonitis is unclear, but it has been suggested that pulmonary dendritic cells and macrophages are immunologically regulated by PD-1 positive T cells.¹⁸ The similarity between CPI-related pneumonitis and pulmonary manifestations of COVID-19 could be explained by a common pathway involving PD-1 and the toll-like receptors (TLRs): in fact, the stimulation of TLRs on CD8+ T lymphocytes decreases the expression of PD-1,¹⁹ and the SARS-CoV-2 spike protein has been demonstrated to bind to TLR and stimulate the production of inflammatory cytokines.²⁰

The role of endothelial dysfunction in COVID-19 and toxicities after immunotherapy

From the initial stages, COVID-19 is accompanied by a coagulopathy characterized by elevated levels of D-dimer and fibrinogen, with minimal changes in prothrombin time, activated partial thromboplastin time, and platelet counts.^{21 22} D-dimer levels at admission and their increase throughout the hospitalization were both correlated with higher mortality.^{12 23 24} Thrombosis is recognized as a

major cause of morbidity and mortality among patients with COVID-19 as it occurs at all levels of the circulatory system^{22 25 26} and in intravenous catheters and extracorporeal circuits.²⁷ The complement cascade is also activated and contributes to microvascular damage and thrombosis.^{28 29} The rates of thromboembolic complications in critically ill patients with COVID-19 were shown to be higher than in other patients hospitalized in ICU for other causes,³⁰ despite the use of prophylactic anticoagulation. SARS-CoV-2 infection outside of the respiratory system seems to follow the abundance of ACE2 beyond the respiratory tract; tropism to renal, myocardial, and gastrointestinal tissues have been described,³¹ likely because endothelial cells in artery and veins throughout the body express ACE2 on their surface.³² The invasion of lung endothelial cells by SARS-CoV-2 represents a crucial point in the worsening of pneumonitis and the transmission to other organs. The resulting endothelialitis can trigger excessive thrombin production in multiple organs and inhibit fibrinolysis; the complement pathway is also activated, leading to the deposition of microthrombi and microvascular dysfunction.³³ As a result, the histopathologic findings of this process are neutrophil extracellular traps, fibrin deposits and/or microthrombi.³⁴ Inflammation itself can be responsible for the procoagulative status in COVID-19 as many proinflammatory cytokines are able to activate the coagulation system. In vivo, high levels of tumor necrosis factor (TNF- α), interleukin (IL)-6 and IL-1 were detected in patients with acute inflammatory conditions³⁵ together with a hypercoagulable status, sometimes evolving into diffuse intravascular coagulation.³⁶ Data from a preliminary study demonstrate that SARS-CoV-2 may directly promote platelet adhesion and aggregation.³⁷ Therefore, a parallel can be drawn between endothelial involvement in COVID-19 and post-CAR-T toxicity. Hay *et al* reported increased levels of circulating endothelial-derived factors, such as von Willebrand and angiopoietin-2, as a sign of endothelial activation, and they also found a correlation with subsequent development of CRS.³⁸

Systemic inflammation and CRS in COVID-19 and immunotherapy

The propagation of the infection and the hyperinflammatory response observed in many individuals affected by COVID-19 depend on the interplay between SARS-CoV-2 and cytokine production. During the first phases of infection, SARS-CoV-2 may antagonize the host’s interferon (IFN) response³⁹ and induce downregulation of the expression of major histocompatibility complex class I molecules on the surface of many cells.⁴⁰ This promotes the escape of the virus from immune recognition and delays its clearance. Lymphopenia is a common finding in COVID-19 and may also contribute to uncontrolled viral replication.³¹ The accumulation of infected cells across different tissues and the hyperstimulation of components of the innate immune system may trigger inappropriate production of cytokines, leading to CRS and causing

further activation of the coagulation and complement cascades. CRS may, in some cases of COVID-19, evolve into hemophagocytic lymphohistiocytosis (HLH), a severe multisystemic inflammatory syndrome characterized by a specific hyperactivation of macrophages, high levels of circulating cytokines, hyperbilirubinemia, and hemolysis, which is associated with high mortality.^{10,41}

CRS is a frequent complication of many immunotherapy approaches. Hematopoietic stem-cell transplantation (HSCT) from familiar haploidentical donors can be complicated by CRS, and CRS may occur in up to 90% of patients receiving stem cells from peripheral blood.⁴² The transplant-related inflammatory syndrome, graft-versus-host disease (GVHD), occurs when donor-derived T cells (the graft) recognize the recipient (the host) as foreign.⁴³ GVHD presents clinically as acute and chronic (cGVHD) with an estimated incidence of 30%–50% and 40%, respectively.^{43,44} Both forms can be localized or can involve multiple systems and lead to CRS. HLH can be a rare and fatal complication of HSCT, potentially related to GVHD, triggered by other mechanisms such as persistent Epstein-Barr virus reactivation.⁴⁵

CAR-T cells, engineered to recognize tumor antigens through a fusion protein comprised of an antibody-like moiety and T cell-signaling domains,⁴⁶ are frequently associated with CRS. In most clinical trials of CAR-T cell therapy for acute B-cell leukemia, the most common severe toxicity was CRS with an overall incidence of 70% and high-grade CRS reported in 15% of patients.⁴⁷ In non-Hodgkin's lymphomas, CRS seemed to occur at a more variable rate (24%–95%).⁴⁸ Fever is the most common initial manifestation of CRS; others may include hypotension, cardiac involvement, dyspnea, hypoxia, and other organ dysfunction.⁸ Although post-CAR-T cell toxicities can resolve spontaneously, most require treatment with anti-inflammatory drugs, and severe cases require intensive care.

Similarly to CAR-T cells, mAbs⁴⁹ and bispecific antibodies, such as blinatumomab, can cause CRS.⁵⁰

Circulating cytokines as markers of disease severity and response to therapies: similarities and differences between COVID-19 and immunotherapy

Recent meta-analyses identified pathways of inflammatory cytokines and chemokines, including IL-6, IL-1b, and TNF- α , that were significantly elevated in patients with severe COVID-19 and led to CRS.⁵¹ IL-6 plays an important role in autoimmune diseases and is recognized as a crucial proinflammatory cytokine.⁵² IL-6 exerts its effects on cells expressing the functional IL-6 receptor (IL-6R), such as T cells, B cells, monocytes, endothelial cells, and hepatocytes.⁵³ IL-6 is essential for recovery from multiple viral infections, but overproduction of IL-6 may be detrimental to viral clearance and survival. The main source of IL-6 during COVID-19 remains elusive; on binding to IL-6R on the surface of target cells, the transduction of the intracellular signal leads to the phosphorylation of the JAK/STAT3 axis.⁵⁴ A number of publications

reported an association between increased IL-6 in peripheral blood and a severe response to SARS-CoV-2, defined as ARDS, CRS, and extrapulmonary damage.⁵⁵ Post-CAR-T CRS shows remarkably high serum concentrations of many inflammatory cytokines, especially IL-6. In CAR-T-related CRS, the release of IL-1 seems to precede that of IL-6; therefore, targeting IL-1 might mitigate or prevent CRS.⁵⁶ IL-6 production was also exhibited after treatment of B cell malignancies with mAbs (rituximab)⁵⁴ and the bispecific antibody blinatumomab.⁵⁷

In a cohort of 69 patients hospitalized with SARS-CoV-2 infection, serum IL-6 concentrations did show a correlation with the severity of the pulmonary disease whereas other cytokines such as IL-2 and IL-4 did not.⁵⁸ A large meta-analysis of 25 COVID-19 studies reports an estimated mean for IL-6 concentrations of 36.7 pg/mL which is nearly a 100-fold difference when compared with four studies on CAR-T cell-induced CRS showing a mean IL-6 of 3110.5 pg/mL.⁵¹ A major limitation of the study may be due to the heterogeneity in the assays used for measuring IL-6 and of the timepoints at which the samples were collected, even though biological differences between COVID-19 and post-CAR-T toxicities are present. First, in patients with COVID-19, IL-6 production is related either directly or indirectly to the viral infection, even if no direct correlation with the viral load has been confirmed, whereas there is no underlying viral replication in patients experiencing CRS after CAR-T cells. Furthermore, IL-6 peaks are transient in CAR-T patients, especially if controlled by therapy, whereas IL-6 levels remain high for a long time in patients with COVID-19.⁴ Thus, IL-6 may represent both a biomarker and a potential therapeutic target for patients hospitalized with COVID-19, which is an attractive concept in the absence of alternative direct-acting antiviral strategies. Proposed clinical cut-off values for IL-6 in this setting have started to emerge, although the sample size of the already published studies is still relatively small.⁵⁹

Other markers including TNF- α , and IFN- γ , and the soluble IL-2 receptor were comparatively lower in COVID-19 than in CAR-T toxicity.⁵¹ Despite their relatively lower serum levels, a recent study showed a potential benefit in early blockage of TNF- α /IFN- γ axis in COVID-19.⁶⁰ In another study, combined TNF- α and IL-6 levels at the moment of hospitalization for COVID-19 were proposed as an early predictive marker of mortality.⁴ Ferritin, a marker of macrophage activation, increases substantially in patients with severe CAR-T-related CRS and was also found to be elevated in COVID-19.⁶¹

In summary, despite the differences in the pathophysiology and in the mean serum levels of some cytokines, COVID-19 shares the elevation of IL-6 with CRS due to CAR-T infusions and, in general, shows an inflammatory profile more similar to IMTX-related CRS than to systemic inflammation of other causes.

Immune-related effects of COVID-19 and immunotherapy on the central nervous system and other organs

Similar to other infections with respiratory coronaviruses, COVID-19 has shown multiple neurological manifestations.⁶² In an analysis of 214 patients with severe COVID-19, the incidence of neurologic symptoms was approximately 30%.⁶³ Various non-specific mild neurological symptoms were reported in up to 40% of hospitalized patients with COVID-19.^{64,65} While direct invasion of the central nervous system (CNS) and microthrombosis play a role in the neurologic complications, immune dysfunction and increased cytokine production can also contribute to CNS damage.^{66–68} The suggested mechanisms related to CNS damage in COVID-19 have also been recognized as a typical immune-mediated complication of CAR-T cells and is referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), which occurs in up to 65% of patients.^{69,70} In ICANS, cytokines cause an alteration of the blood–brain barrier.⁷¹ Most cases of neurotoxicity and CRS are reversible with targeted treatment and supportive care. Rituximab, an anti-CD20 antibody used in the treatment of B cell lymphomas, can cause posterior reversible encephalopathy, a rare clinical condition manifesting with headache, altered level of consciousness, convulsions, visual loss, and reversible cerebral edema visible on brain MRI.⁴⁹

Finally, similar to many other viruses, systemic manifestations of COVID-19 due to involvement of the gastrointestinal system, liver, kidneys, heart, endocrine system, and the skin are reported relatively frequently.^{36,72–76} COVID-19 can also cause a systemic inflammatory syndrome similar to some autoimmune diseases.⁷⁷ Although a limited proportion of all patients with COVID-19 worldwide are under the age of 15 years, several reports from European and US groups have reported cases of children with a severe inflammatory syndrome similar to Kawasaki disease or toxic shock syndrome.⁷⁸

What we have learned from immunotherapy that can be used for treating COVID-19

A detailed description of the methods that we used for performing this search is outlined in online supplemental 1. [Table 1](#) shows a list of the treatments and targets currently under investigation for COVID-19.

Cellular immunotherapy for COVID-19

Cellular immunotherapy may be used in treating COVID-19 by either targeting virus-infected cells or modulating the inflammatory pathways leading to CRS. However, no studies have reported treatment with SARS-CoV-2-specific T cells to date. T cell clones specifically recognizing SARS-CoV-2 were identified from convalescent patients and their use was proposed for the prevention or early treatment of SARS-CoV-2 infection in immunocompromised patients with blood disorders or after bone marrow transplantation.⁷⁹ Banks of allogeneic, third-party ‘off-the-shelf’ T cell products could be considered for timely administration of CAR-T cells,

but much remains unknown about safety and efficacy of this approach at this time, with primary concerns for triggering or worsening CRS or ICANS. An alternative technique to redirect the immune system toward antigens of interest involves the use of T cells carrying an engineered tumor-recognizing T cell receptor (TCR). TCR-engineered T cells have shown efficacy in solid tumors as melanoma, esophageal cancer, synovial sarcoma, and Wilms tumor,⁸⁰ with encouraging results in acute myeloid leukemia.⁸¹ In the majority of clinical trials, the infusion of ex vivo expanded TCR-modified cells was well tolerated.⁸² However, there are some data to suggest TCR-engineered cells may cause adverse on-target, off-tumor effects, as well as off-target effects. In the field of antiviral therapy, TCR-engineered T cells can be used to target viral antigens, such as for cytomegalovirus, and offer an exciting approach to improve the treatment or prevention of viral infections in high-risk settings such as T cell-depleted HSCT and delayed immune reconstitution.⁸³ So far, TCR-engineered T cells against SARS-CoV-2 antigens have not been investigated and may share some of the limitations as CAR-T cells.

Natural killer (NK) cells, an important component of the innate immune system, play a pivotal role in immune surveillance⁸⁴ and can also be used as adoptive IMTX. Haploidentical and third party-expanded NK cells have been used for relapsed and refractory myeloid leukemia, either as post-HSCT infusion or as isolated therapy, showing good response rates and very low rates of toxic effects.⁸⁵ As an alternative to CAR-T cells, NK cells engineered to express a CAR (CAR-NK) are candidate effectors for cancer treatment. NK cells can be generated off the shelf from an allogeneic source, such as cord blood, to be safely administered without the need for full human leukocyte antigen matching and eliminating the need to produce a unique CAR product for each patient.⁸⁶ An in vitro study indicates ‘off-the-shelf’ generated anti-SARS-CoV-2 CAR-NK cells exhibit a high efficacy at targeting and killing cells infected with SARS-CoV-2.⁸⁷ One phase II/III trial testing the in vivo potential of these cells is open and recruiting in China. Other trials are studying the effects of cryopreserved, allogeneic, off-the-shelf, non-transgenic NK cells as a means of restoring the depressed NK activity observed during COVID-19.⁸⁸ Treatment with NK cells derived from human placental CD34+ cells and culture-expanded (CYNK-001) are also being investigated in a clinical trial (ClinicalTrials.gov Identifier: NCT04365101).

Mesenchymal stromal cells (MSCs) are a heterogeneous population of stromal cells found throughout the body that migrate to specific tissues in the context of remodeling and regeneration. They reportedly play an immunomodulatory role in tumor microenvironment, also contributing to local tumor aggressiveness in some hematological malignancies.^{89–91} Due to their anti-inflammatory effects and their interaction with macrophages, many trials use MSC to treat aggressive GVHD,⁹² but in some cases MSCs were also engineered

Table 1 Shared mechanisms of action between COVID-19 and immunotherapy, and potential common therapeutic strategies

Molecular target	Role in immunotherapy	Role in COVID-19	Trials in COVID-19		Comments
			Available drugs	Results in COVID-19	
IL-6	Elevation during CRS following CAR-T and mAb infusion. ¹¹⁹	Elevated levels correlate with severity of disease. ^{55,56}	Tocilizumab ¹²⁸ Sarilumab ¹²⁸	Active trials: 38 Completed: 8 Active trials: 9 Completed: 3	Recommended in recently hospitalized patients with severe respiratory disease in combination with Dex. ^{123–125,127} No clear evidence in patients requiring hospitalization. ¹²⁸ The SARICOR Study is testing whether the administration of sarilumab (an IL-6 receptor inhibitor) in hospitalized patients with COVID-19, pulmonary infiltrates and a high IL-6 or D-dimer serum level could reduce the progression of ARDS. ¹⁴⁵
JAK/STAT intracellular signaling	Approved for steroid-refractory GVHD. ¹³¹	JAK kinases are activated after stimulation of IL receptors	Baricitinib Ruxolitinib	Active trials: 9 Completed: 1 Active trials: 16 Completed: 1	Better outcome for hospitalized patients in association with remdesivir compared with remdesivir alone. ¹³⁴ Apparent efficacy at reducing progression of ARDS and need for respiratory support. ¹³²
IL-1	In CAR-T-related CRS, the release of IL-1 seems to precede that of IL-6. ⁵⁶	IL-1b was significantly elevated in patients with severe COVID-19. ¹⁴⁶	Anakinra	Active trials: 14 Completed: 2	IL-1 may precede the production of IL-6 in COVID-19, as it seems to happen during CAR-T toxicity
IFN- γ	Blocking IFN is approved for familial HLH, not approved for post-IMTX CRS.	Potential benefit in early blockage of TNF- α /IFN- γ axis in COVID-19. ⁶⁰	Emapalumab	Active trials: 1 Completed: 0	Comparing anakinra to emapalumab which demonstrated efficacy in pediatric HLH ¹³⁷
TNF- α	Largely used in the treatment of severe forms of autoimmune diseases.	TNF- α is elevated in early phases of disease. ⁵¹	Infliximab	Active trials: 1 Completed: 1	Potential high risk of bacterial superinfection
Plasmin	Dysregulated in SOS/VOD and DIC for all causes. ¹⁴¹	Hypercoagulation is secondary to endothelialitis and ACE2-dependent hypofibrinolysis ³³	Defibrotide	Active trials: 4 Completed: 0	Potential benefit in association with other anticoagulants
C5 protein of the complement	Hyperactivated during TA-TMA and HUS. ¹⁴⁷	Both C3 and C5 inhibitors showed a robust anti-inflammatory response, reflected by a steep decline in IL-6 levels, marked lung function improvement, and resolution of SARS-CoV-2-associated ARDS. ¹⁴⁴	Eculizumab	Active trials: 1 Completed: 0	Potential benefit in patients with consumption of complement factors and signs of microthrombosis and kidney injury. Contraindicated if there is bacterial infection

Continued



Table 1 Continued

Molecular target	Role in immunotherapy	Role in COVID-19	Available drugs	Trials in COVID-19	Results in COVID-19	Comments
All pro-inflammatory cytokines	CRS and ICANS are associated with remarkably high serum concentrations of many inflammatory cytokines.	Many proinflammatory cytokines are produced after SARS-CoV-2 infection. They cause tissue damage, promote NETs, and activate the coagulation and complement systems.	Dexamethasone (Dex)	Active trials: 21 Completed: 2	At the time of writing, Dex is the only drug that has shown a reduction in mortality due to COVID-19 ¹¹⁶	Current recommendation for Dex in COVID-19 is restricted to patients experiencing initial ARDS and signs of CRS
Spike protein of SARS-CoV-2	No recognized role of ACE2 receptor in IMTX.	It is the protein that mediated the entry of the viral particles into the cells ^{1,49}	Mesenchymal cells (MSC) mAbs	Active trials: 49 Completed: 5 Active trials: 33 Completed: 1	First trials show capacity of MSC to attenuate lung and systemic inflammation ^{96 148} Chi et al ¹¹¹ isolated, from convalescent patients with COVID-19, 3 mAbs displaying neutralization against SARS-CoV-2	Some limit due to the time of manufacturing, but potential use of third-party sources for off-the-shelf production Utility for treating patients until a vaccine will be available, and then to transfer adoptive immunity to immunosuppressed patients
			Anti-spike CAR-T cells	Active trials: 0 Completed: 0	No results from anti-spike CAR-T so far	CAR-T cells are very successful in the treatment of hematologic tumors, ¹⁵⁰ but there remain many complications, including severe CRS and ICANS, that have discouraged their use in COVID-19
			Anti-spike NK cells	Active trials: 6 Completed: 0	NK and CAR-NK cells seem to control viral replication without increased risk of CRS ⁷⁵	Compared with CAR-T, the use of wild-type NK and NK-CAR cells seems to be safer even if there is no definitive answer about their efficacy
			Anti-spike TCR-engineered cells	Active trials: 0 Completed: 0	No data available	TCR-engineered T cells have the same limitations of CAR-T for the treatment of active disease. However, as anti-viral mAbs, they might be useful in the future to confer adoptive cell-mediated immunity against SARS-CoV-2 in immunocompromised patients. ¹⁵¹

ARDS, acute respiratory distress syndrome; CAR-T, chimeric antigen receptor-T cell; CRS, cytokine release syndrome; DIC, diffuse intravascular coagulation; GVHD, graft-versus-host disease; HLH, hemophagocytic lymphohistiocytosis; HUS, hemolytic uremic syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ICU, intensive care unit; IFN- γ , interferon γ ; IL, interleukin; IMTX, immunotherapy; mAb, monoclonal antibody; NETs, neutrophil extracellular traps; NIH, National Institutes of Health; NK, natural killer; SOS/VOD, sinusoidal obstruction syndrome/veno-occlusive disease; TA-TMA, transplant-associated thrombotic microangiopathy; TCR, T cell receptor; TNF- α , tumor necrosis factor- α .

to hyperexpress cytokines as IFN- γ and inoculated within tumor tissue.⁹³ The administration of systemic third-party MSC in patients with steroid refractory acute and chronic GVHD showed response rates up to 70%.⁹⁴ Cell therapy with MSCs is an appealing approach to target many inflammatory patterns altogether. Results from two small trials in patients with COVID-19 showed clinical and radiological improvement after MSC infusion with no toxic effects.^{95 96} Another trial showed that exosomes isolated from MSC and infused intravenously can help in mitigating severe manifestations of COVID-19.⁹⁷ Forty-nine clinical trials are testing the infusion of MSC derived from autologous or allogeneic adipose tissue, dental pulp, bone marrow, or from cord blood Wharton's jelly for the treatment of COVID-19.

Antibody-based immunotherapy to target the virus–cell interaction

Neutralizing antibodies can block the transmission of the SARS-CoV-2 and its spread throughout the body. Targeting the SARS-CoV-2 spike protein seems to be the most efficient strategy in preventing virus–cell interactions. Several vaccines encoding the stabilized SARS-CoV-2 spike protein recently showed promising efficacy in terms of inducing a protein-specific antibody response with an acceptable rate of adverse events.^{98–102} Nonetheless, strategies to rapidly block the infection are still needed for patients who are currently affected by COVID-19 and for the patients who will not respond to the vaccine in the future. Plasma pooled from volunteers who recovered from the SARS-CoV-2 infection was reported to be effective in some studies,¹⁰³ including in a recent randomized trial showing efficacy if given within the first 72 hours from the onset of symptoms.¹⁰⁴ However, contrasting evidence has emerged from other publications, including a prospective trial on more than 300 patients, that failed to demonstrate superiority of convalescent plasma over placebo.¹⁰⁵ The major limitations of this approach are the availability of donors, safety concerns for allergic reactions, and the use of blood-derived products. Another limitation is that by the time the patients are sick, neutralizing antibodies are already present,¹⁰⁶ and the value of adoptively transferred immunoglobulins becomes more limited; conversely, non-neutralizing antibodies produced by B cells may enhance SARS-CoV-2 infection through antibody-dependent enhancement, further exacerbating organ damage.¹⁰⁷ Approaches using polyclonal intravenous immunoglobulins (IVIGs) collected from the general population, which are beneficial in some autoimmune conditions,¹⁰⁸ did not show clear evidence of benefit for ameliorating ARDS or mitigating CRS in patients with COVID-19.¹⁰⁹ Data from several clinical trials will clarify soon whether IVIG can be considered for hospitalized patients. IVIG might be contemplated for the treatment of the rare Guillain-Barre syndrome during the course of COVID-19.¹¹⁰

The synthesis of anti-SARS-CoV-2 mAbs on a large scale would be more cost-effective and sustainable compared

with donor-derived antibodies. Identifying the right viral epitope to target is the first step for a successful strategy. Chi *et al* isolated, from convalescent patients with COVID-19, three mAbs displaying neutralization against SARS-CoV-2.¹¹¹ Several other synthetic mAbs are already being tested in clinical trials all around the world. One being investigated in two trials is the combination of two mAbs, REGN10987 and REGN10933, called 'REGN-COV2', which showed efficacy and good toxicity profile in non-human primates and hamsters.¹¹² The trial has stopped the enrollment of patients hospitalized with severe COVID-19 for lack of efficacy, but the Food and Drug Administration (FDA) has approved the use of REGN-COV2 cocktail for adult patients with recently diagnosed mild to moderate COVID-19 at high risk of progression.

Targeting the cytokine-mediated immune dysfunction in COVID-19: corticosteroids, mAbs, and selective inhibitors borrowed from immunotherapy

Corticosteroids such as dexamethasone are potent anti-inflammatory drugs that are broadly used in the treatment of immune-mediated diseases, including autoimmune diseases, GVHD, CAR-T toxicity, toxic effects of mAbs and sepsis.^{113 114} Since the early days of the SARS-CoV-2 pandemic, many groups have published reports and results of prospective trials using dexamethasone in patients with COVID-19. Many of these trials showed an advantage of using corticosteroids; among them, the RECOVERY trial, a controlled open-label trial comparing oral and intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days versus usual care alone. The RECOVERY trial showed a lower 28-day mortality among patients of the dexamethasone group who were receiving either invasive mechanical ventilation or oxygen at randomization, but not among those receiving no respiratory support.¹¹⁵ A meta-analysis of seven randomized trials on 1703 critically ill patients with COVID-19 confirmed the role of dexamethasone in reducing the mortality at day 28.¹¹⁶ At the time of writing, dexamethasone is the only drug that has shown a reduction in mortality due to COVID-19. There are still unanswered questions as to why the dosage and timing of administration are crucial to the outcome, especially in severe cases. In fact, administering glucocorticoids too early may favor the viral replication, but prolonged administration might delay viral clearance. For this reason, the current recommendation for dexamethasone in COVID-19 is restricted to patients experiencing initial ARDS and signs of CRS. Since dexamethasone has been shown to be effective in reducing IL-6,⁴ an early measure of serum IL-6 on patients' admission to the hospital might be used in identifying patients at higher risk of CRS and given dexamethasone immediately. Currently, 21 clinical trials are geared towards addressing those questions.

The ability of mAbs to block cytokines, TNF- α and ILs is of particular interest when treating chronic inflammatory conditions such as autoimmune diseases, transplant rejection, and GVHD.¹¹⁷ IL-6 and its receptor, IL-6R, are druggable




Figure 1 Pathways of immune dysfunction in COVID-19 and immunotherapy-related adverse events. ARDS, acute respiratory distress syndrome; CAR-T, chimeric antigen receptor-T cell; GVHD, graft-versus-host disease; IFN, interferon; IL, interleukin; mAbs, monoclonal antibodies; MSC, mesenchymal stromal cell; NK, natural killer; TCR, T cell receptor; TNF- α , tumor necrosis factor- α . Created with BioRender.com.

targets of interest in CRS of any origin. The anti-IL-6R mAb, tocilizumab, was developed two decades ago for the treatment of severe autoimmune diseases.¹¹⁸ CAR-T and mAbs can cause CRS by inducing a massive release of IL-6, and tocilizumab is now the standard of care in the management of severe CRS after CD19-specific CAR-T cells.¹¹⁹ In COVID-19, real-world experience with tocilizumab has shown that a substantial proportion of patients with severe pneumonia and fever improved clinically and radiologically. Increased laboratory parameters such as C reactive protein in patients with COVID-19 appear to decrease significantly with tocilizumab, and lymphocyte levels also return to normal.¹²⁰⁻¹²² Worldwide, as of March 22, 2021, 38 clinical trials evaluating the effectiveness and safety of tocilizumab for treating patients with COVID-19 pneumonia are open, and 8 studies have been completed. In October 2020, the results of three prospective trials were published. A randomized North American study failed to demonstrate any superiority of tocilizumab over placebo in terms of required intubation, clinical respiratory improvement, and survival.¹²³ Another multicenter trial from Italy showed similar results.¹²⁴ Interestingly, a French group reported a reduction in the probability of non-invasive ventilation, mechanical ventilation, or death by day 14, but no difference on day 28 mortality.¹²⁵ A large multicenter non-randomized cohort study showed

higher overall survival with tocilizumab given in the first 2 days of ICU admission,¹²⁶ but recent results from a phase 3 randomized controlled trial did not show superiority of tocilizumab over a placebo group.¹²⁷ Another anti IL-6 antibody that has been proposed is sarilumab; despite some positive preliminary evidence, a phase 3 trial has failed to demonstrate a benefit of the drug over a placebo in a large cohort of hospitalized patients requiring oxygen.¹²⁸ Based on all the published data, the National Institutes of Health COVID-19 Treatment Guideline Panel currently recommends the early use of tocilizumab in combination with corticosteroids for certain hospitalized patients who exhibit rapid respiratory decompensation, unless contraindications such as use of immunosuppressive drugs, severe neutropenia, and active bacterial or fungal infection are present.

Another interesting target to block the inflammatory signals might be the downstream pathway of IL-6R as the JAK kinases are phosphorylated after IL-6 binds to its receptor, and they are responsible for translating the signal.¹²⁹ Ruxolitinib, a JAK inhibitor, is used in chronic myeloid neoplasms¹³⁰ and in the treatment of steroid-refractory cGVHD.¹³¹ In a retrospective study and case series, ruxolitinib was shown to reduce the progression of ARDS and need of respiratory assistance in COVID-19.¹³² Sixteen trials using ruxolitinib are

currently ongoing, with one phase 3 randomized clinical trial completed. Baricitinib, another JAK inhibitor, is currently investigated in nine trials. The results of a large prospective trial on 1000 patients were recently published, and when compared with remdesivir alone,¹³³ the association of baricitinib+remdesivir showed efficacy in reducing recovery time and accelerating improvement in clinical status among patients with COVID-19, most notably among those receiving high-flow oxygen or non-invasive ventilation.¹³⁴

Anakinra is an antagonist of the IL-1R approved for the treatment of severe rheumatoid arthritis.¹³⁵ Clinical trials showed efficacy of anakinra in treating neurotoxicity (ICANS) after CAR-T cell infusion.⁵⁶ Huet *et al* reported lower rates of ICU admissions, respiratory support, and death in 52 consecutive patients who received anakinra when compared with a historical cohort.¹³⁶ Currently, 14 clinical trials are evaluating the efficacy of anakinra in reducing the number of patients requiring mechanical ventilation. One of them is comparing anakinra with emapalumab, an anti-IFN- γ mAb that demonstrated efficacy in pediatric HLH.¹³⁷

Alternative targets: other cytokines, coagulation, and complement

Infliximab,¹³⁸ an anti-TNF- α mAb used in autoimmune diseases, has shown effectiveness in treating patients with COVID-19. Surprisingly, only three clinical trials are targeting TNF- α in the COVID-19 setting. Few trials are also testing a mAb against IL-8; other authors have suggested a role for the IL-33-ST2 axis in the chain of events leading to severe COVID-19,¹³⁹ but there are no clinical trials currently targeting these molecules. There are also no trials combining anti-IL-6 and anti-TNF- α , despite both cytokines being independently associated with mortality. These two cytokines have different pathways, and the anti-inflammatory effect might be more potent if they are targeted in combination. Other trials are testing the benefit of direct administration of cytokines such as IL-7 with the aim of modulating the inflammation and increasing CD4+ and CD8+ counts, based on encouraging results from a Belgian pilot trial.¹⁴⁰

Four trials are investigating the role of defibrotide, the only approved drug for the treatment of sinusoidal obstruction syndrome/veno-occlusive disease, which is a syndrome characterized by endothelial dysfunction occurring after HSCT.¹⁴¹ However, there are no preliminary data available about the utility of this approach. Targeting the complement with eculizumab, an anti-C5 mAb used in the treatment of hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria,^{142 143} and with the anti-C3 AMY-101¹⁴⁴ may be an effective alternative strategy, as suggested by preliminary results.

A summary of all the above-described mechanisms is outlined in [figure 1](#).

FINAL CONSIDERATIONS

COVID-19 is an inflammatory disease caused by a viral infection. The ultimate strategy to stop the SARS-CoV-2

pandemic is a vaccine campaign covering the majority of the population worldwide. A variety of vaccines have been recently approved in different countries and are increasing in availability to high-risk and low-risk individuals. Until then, social distancing measures will remain the most efficient way to limit the spread of the disease and protect the most sensitive individuals. Immunotherapeutic approaches to modulate the immune system may help to treat patients with COVID-19 by mitigating viral replication and stemming the cascade of inflammatory events induced by SARS-CoV-2.

To date, a few immunomodulating therapies have been successful in the treatment of COVID-19. Corticosteroids have demonstrated efficacy in reducing the mortality in patients with COVID-19 with ARDS, and the FDA approved the use of the REGN-COV2 mAb cocktail for patients with recent infection, mild symptoms, and high risk of progression. Baricitinib, an anti-JAK agent, is now recommended in association with remdesivir for hospitalized patients. Tocilizumab in combination with dexamethasone has recently received recommendation for some group of patients with rapidly evolving respiratory disease. Other anti-IL-6 agents, such as sarilumab, have shown promising preliminary results, as well as ruxolitinib and other anti-inflammatory mAbs such as anakinra. Cell therapy and other inhibitors, such as defibrotide and eculizumab, have potential for benefit and are being tested in many ongoing clinical trials. Stratification of patients based on values of the cytokines that appear more involved in the underlying COVID-19 inflammatory process might expand our knowledge on the before-mentioned drugs in specific subgroups. The rapid development of several anti-SARS-CoV-2 vaccines, and the volume of clinical trials testing anti-inflammatory drugs for COVID-19 based on what we have learned from immunotherapy, highlight the capability of modern medicine to produce high-quality evidence and offer effective strategies in the middle of a pandemic.

Contributors LI, AC, FM and JAH conceived the structure of the manuscript. LI and LAT wrote the manuscript with the support of AC, SG, FM and JAH, and drew the table. LAT performed the search on clinicaltrials.gov. LI drew the figure. All authors provided critical feedback and helped shape the research, analysis and manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests JAH is a consultant for Gilead Sciences, Amplyx, Allovir, Allogene therapeutics, CRISPR therapeutics, Takeda; and provides research support from Takeda, Allovir, Karius, Gilead Sciences. SG reports research current or past funding from Bristol-Myers Squibb, Genentech, Immune Design, Agenus, Janssen R&D, Pfizer, Takeda, and Regeneron; and past consultancy and/or advisory roles for Merck, Neon Therapeutics and OncoMed.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible

for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Lorenzo Iovino <http://orcid.org/0000-0002-3165-1899>

REFERENCES

- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020;20:533–4.
- Zheng KI, Feng G, Liu WY. Extrapulmonary complications of COVID-19: a multisystem disease? *J Med Virol* 2020.
- Rosen HR, O'Connell C, Nadim MK, et al. Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection. *J Med Virol* 2021;93:2645–53.
- Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020;26:1636–43.
- Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol* 2020;20:651–68.
- Zumla A, Rao M, Wallis RS, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. *Lancet Infect Dis* 2016;16:e47–63.
- Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. *Critical Care* 2017;21:89.
- Thakar MS, Kearn TJ, Malarkannan S. Controlling cytokine release syndrome to harness the full potential of CAR-Based cellular therapy. *Front Oncol* 2019;9:1529.
- Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A* 2020;117:11727–34.
- Quan C, Li C, Ma H, et al. Immunopathogenesis of coronavirus-induced acute respiratory distress syndrome (ARDS): potential infection-associated hemophagocytic lymphohistiocytosis. *Clin Microbiol Rev* 2020;34.
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324:782–93.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020;395:1054–62.
- Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. *PLoS One* 2020;15:e0235653.
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine* 2020;8:475–81.
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med Overseas Ed* 2020;383:120–8.
- Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. *Exp Mol Med* 2018;50:1–11.
- Koyama N, Iwase O, Nakashima E, et al. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. *BMC Pulm Med* 2018;18:23.
- Liu Y, Zugazagoitia J, Ahmed FS, et al. Immune cell PD-L1 localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. *Clin Cancer Res* 2020;26:970–7.
- Zahm CD, Colluru VT, McIlwain SJ, et al. TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8⁺ T Cells. *Cancer Immunol Res* 2018;6:1364–74.
- Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via Toll-like receptor 4 signaling in murine and human macrophages. *Heliyon* 2021;7:e06187.
- Kamel MH, Yin W, Zavarro C, et al. Hyperthrombotic milieu in COVID-19 patients. *Cells* 2020;9:2392.
- Lazzaroni MG, Piantoni S, Masneri S, et al. Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. *Blood Rev* 2021;46:100745.
- Gayam V, Chobufo MD, Merghani MA, et al. Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York. *J Med Virol* 2021;93:812–9.
- Yu H-H, Qin C, Chen M, et al. D-Dimer level is associated with the severity of COVID-19. *Thromb Res* 2020;195:219–25.
- Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020;135:2033–40.
- Elgendy IY, Kolte D, Mansour MK. Incidence, predictors, and outcomes of thrombotic events in hospitalized patients with viral pneumonia. *Am J Cardiol* 2021.
- Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med* 2020;46:1603–6.
- Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. *J Clin Invest* 2020;130:3950–3.
- Ghebrehiet B, Peerschke EI. Complement and coagulation: key triggers of COVID-19-induced multiorgan pathology. *J Clin Invest* 2020;130:5674–6.
- Poissy J, Goutay J, Caplan M. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. *Circulation* 2020;142:184–6.
- Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med* 2020;26:1017–32.
- Hamming I, Timens W, Bultuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004;203:631–7.
- Karmouty-Quintana H, Thandavarayan RA, Keller SP, et al. Emerging mechanisms of pulmonary vasoconstriction in SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) and potential therapeutic targets. *Int J Mol Sci* 2020;21:8081.
- Radermecker C, Detrembleur N, Guiot J, et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. *J Exp Med* 2020;217. doi:10.1084/jem.20201012. [Epub ahead of print: 07 Dec 2020].
- Karki R, Sharma BR, Tuladhar S, et al. COVID-19 cytokines and the hyperactive immune response: synergism of TNF- α and IFN- γ in triggering inflammation, tissue damage, and death. *bioRxiv* 2020. doi:10.1101/2020.10.29.361048. [Epub ahead of print: 29 Oct 2020].
- AlSamman M, Caggiola A, Ganguli S, et al. Non-Respiratory presentations of COVID-19, a clinical review. *Am J Emerg Med* 2020;38:2444–54.
- Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol* 2020;13:120.
- Hay KA, Hanafi L-A, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood* 2017;130:2295–306.
- Sa Ribero M, Jouvenet N, Dreux M, et al. Interplay between SARS-CoV-2 and the type I interferon response. *PLoS Pathog* 2020;16:e1008737.
- Flower TG, Buffalo CZ, Hooy RM, et al. Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion. *bioRxiv* 2020. doi:10.1101/2020.08.27.270637. [Epub ahead of print: 27 Aug 2020].
- Lima R, Filho CC, Ferreira Filho CM. Hemophagocytic syndrome and COVID-19. *Respir Med Case Rep* 2020;31:101162.
- Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. *Biology of Blood and Marrow Transplantation* 2019;25:2431–7.
- Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. *Br J Haematol* 2019;187:563–72.
- Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. *Blood* 2015;125:606–15.
- Sandler RD, Carter S, Kaur H, et al. Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)-time to reappraise with modern diagnostic and treatment strategies? *Bone Marrow Transplant* 2020;55:307–16.
- Cirillo M, Tan P, Sturm M, et al. Cellular immunotherapy for hematologic malignancies: beyond bone marrow transplantation. *Biology of Blood and Marrow Transplantation* 2018;24:433–42.
- Brudno JN, Kochenderfer JN. Recent advances in car T-cell toxicity: mechanisms, manifestations and management. *Blood Rev* 2019;34:45–55.
- Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. *Biology of Blood and Marrow Transplantation* 2019;25:e123–7.

- 49 Hansel TT, Kropshofer H, Singer T, *et al.* The safety and side effects of monoclonal antibodies. *Nat Rev Drug Discov* 2010;9:325–38.
- 50 Jain T, Litzow MR. No free rides: management of toxicities of novel immunotherapies in all, including financial. *Hematology* 2018;2018:25–34.
- 51 Leisman DE, Ronner L, Pinotti R, *et al.* Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. *The Lancet Respiratory Medicine* 2020;8:1233–44.
- 52 Mitsuyama K, Toyonaga A, Sasaki E, *et al.* Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. *Gut* 1995;36:45–9.
- 53 Choy EH, De Benedetti F, Takeuchi T, *et al.* Translating IL-6 biology into effective treatments. *Nat Rev Rheumatol* 2020;16:335–45.
- 54 Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol* 2015;16:448–57.
- 55 Copaescu A, Smibert O, Gibson A, *et al.* The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J Allergy Clin Immunol* 2020;146:518–34.
- 56 Strati P, Neelapu SS. Chimeric antigen Receptor-Engineered T cell therapy in lymphoma. *Curr Oncol Rep* 2019;21:38.
- 57 Klingler M, Brandl C, Zugmaier G, *et al.* Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific bite antibody blinatumomab. *Blood* 2012;119:6226–33.
- 58 Zhang P, Shi L, Xu J, *et al.* Elevated interleukin-6 and adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. *Immunogenetics* 2020;72:431–7.
- 59 Chen LYC, Hoiland RL, Stukas S, *et al.* Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur Respir J* 2020;56:2003006.
- 60 Karki R, Sharma BR, Tuladhar S, *et al.* COVID-19 cytokines and the hyperactive immune response: synergism of TNF- α and IFN- γ in triggering inflammation, tissue damage, and death. *bioRxiv* 2020. doi:10.1101/2020.10.29.361048. [Epub ahead of print: 29 Oct 2020].
- 61 Cheng L, Li H, Li L, *et al.* Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *J Clin Lab Anal* 2020;34:e23618.
- 62 Ellul MA, Benjamin L, Singh B. Neurological associations of COVID-19. *Lancet Neurol* 2020;19:767–83.
- 63 Mao L, Jin H, Wang M, *et al.* Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol* 2020;77:683–90.
- 64 Divani AA, Andalib S, Biller J, *et al.* Central nervous system manifestations associated with COVID-19. *Curr Neurol Neurosci Rep* 2020;20:60.
- 65 Varatharaj A, Thomas N, Ellul MA, *et al.* Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry* 2020;7:875–82.
- 66 Achar A, Ghosh C. COVID-19-Associated neurological disorders: the potential route of CNS invasion and blood-brain barrier relevance. *Cells* 2020;9:2360.
- 67 Najjar S, Najjar A, Chong DJ, *et al.* Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. *J Neuroinflammation* 2020;17:231.
- 68 Nikbakht F, Mohammadkhanizadeh A, Mohammadi E. How does the COVID-19 cause seizure and epilepsy in patients? the potential mechanisms. *Mult Scler Relat Disord* 2020;46:102535.
- 69 Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. *Am J Hematol* 2019;94:S42–9.
- 70 Neelapu SS, Tummala S, Kebriaei P, *et al.* Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. *Nat Rev Clin Oncol* 2018;15:47–62.
- 71 Gust J, Hay KA, Hanafi L-A, *et al.* Endothelial activation and Blood-Brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov* 2017;7:1404–19.
- 72 Kullar R, Patel AP, Saab S. Hepatic injury in patients with COVID-19. *J Clin Gastroenterol* 2020;54:841–9.
- 73 Barbosa da Luz B, de Oliveira NMT, França Dos Santos IW. An overview of the gut side of the SARS-CoV-2 infection. *Intestinal research* 2020.
- 74 Ye L, Yang Z, Liu J, *et al.* Digestive system manifestations and clinical significance of coronavirus disease 2019: a systematic literature review. *J Gastroenterol Hepatol* 2020. doi:10.1111/jgh.15323. [Epub ahead of print: 05 Nov 2020].
- 75 van Eeden C, Khan L, Osman MS, *et al.* Natural killer cell dysfunction and its role in COVID-19. *Int J Mol Sci* 2020;21:6351.
- 76 Lundholm MD, Poku C, Emanuele N, *et al.* SARS-CoV-2 (COVID-19) and the endocrine system. *J Endocr Soc* 2020;4:bvaa144.
- 77 Icenogle T. COVID-19: infection or autoimmunity. *Frontiers in Immunology* 2020;11:11.
- 78 Kaushik A, Gupta S, Sood M, *et al.* A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. *Pediatr Infect Dis J* 2020;39:e340–6.
- 79 Keller MD, Harris KM, Jensen-Wachspress MA, *et al.* SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. *Blood* 2020;136:2905–17.
- 80 Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. *Front Immunol* 2019;10:2250.
- 81 Chapuis AG, Egan DN, Bar M, *et al.* T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. *Nat Med* 2019;25:1064–72.
- 82 Li D, Li X, Zhou W-L, *et al.* Genetically engineered T cells for cancer immunotherapy. *Sig Transduct Target Ther* 2019;4:35.
- 83 Wagner EK, Qerqez AN, Stevens CA, *et al.* Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display. *Journal of Biological Chemistry* 2019;294:5790–804.
- 84 Caligiuri MA. Human natural killer cells. *Blood* 2008;112:461–9.
- 85 Lee DA, Denman CJ, Rondon G, *et al.* Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. *Biol Blood Marrow Transplant* 2016;22:1290–8.
- 86 Liu E, Marin D, Banerjee P, *et al.* Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. *N Engl J Med* 2020;382:545–53.
- 87 Ma M, Badeti S, Geng K, *et al.* Efficacy of targeting SARS-CoV-2 by CAR-NK cells. *bioRxiv* 2020. doi:10.1101/2020.08.11.247320. [Epub ahead of print: 12 Aug 2020].
- 88 Li M, Guo W, Dong Y, *et al.* Elevated Exhaustion Levels of NK and CD8⁺ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease. *Front Immunol* 2020;11:580237.
- 89 Pacini S, Montali M, Mazziotta F, *et al.* Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma. *Oncotarget* 2019;10:6781–90.
- 90 Rambaldi B, Diral E, Donsante S. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. *Ann Hematol* 2020.
- 91 Pittenger MF, Discher DE, Péault BM, *et al.* Mesenchymal stem cell perspective: cell biology to clinical progress. *NPJ Regen Med* 2019;4:22.
- 92 Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. *Blood* 2018;131:2651–60.
- 93 Sartoris S, Mazzocco M, Tinelli M, *et al.* Efficacy assessment of Interferon-Alpha-Engineered mesenchymal stromal cells in a mouse plasmacytoma model. *Stem Cells Dev* 2011;20:709–19.
- 94 Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, *et al.* Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation* 2014;20:1580–5.
- 95 Shu L, Niu C, Li R, *et al.* Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. *Stem Cell Res Ther* 2020;11:361.
- 96 Meng F, Xu R, Wang S, *et al.* Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. *Signal Transduction and Targeted Therapy* 2020;5:172.
- 97 Sengupta V, Sengupta S, Lazo A, *et al.* Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. *Stem Cells Dev* 2020;29:747–54.
- 98 Anderson EJ, Roupheal NG, Widge AT. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N Engl J Med* 2020.
- 99 Baden LR, El Sahly HM, Essink B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2020.
- 100 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine* 2020;383:2603–15.
- 101 Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397:99–111.
- 102 Sadoff J, Le Gars M, Shukarev G, *et al.* Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. *N Engl J Med Overseas Ed* 2021.

- 103 Liu STH, Lin H-M, Baine I, *et al.* Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. *Nat Med* 2020;26:1708–13.
- 104 Libster R, Pérez Marc G, Wappner D, *et al.* Early high-titer plasma therapy to prevent severe Covid-19 in older adults. *N Engl J Med* 2021;384:610–8.
- 105 Simonovich VA, Burgos Pratz LD, Scibona P, *et al.* A randomized trial of convalescent plasma in Covid-19 severe pneumonia. *N Engl J Med* 2021;384:619–29.
- 106 Crawford KHD, Dingens AS, Eguia R. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *J Infect Dis* 2020.
- 107 Tay MZ, Poh CM, Rénia L, *et al.* The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020;20:363–74.
- 108 Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. *Int J Rheum Dis* 2018;21:64–9.
- 109 Pei L, Zhang S, Huang L, *et al.* Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis. *Pol Arch Intern Med* 2020;130:726–33.
- 110 Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, *et al.* COVID-19 and Guillain-Barre syndrome: a systematic review of case reports. *Wellcome Open Res* 2020;5:107.
- 111 Chi X, Yan R, Zhang J, *et al.* A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. *Science* 2020;369:650–5.
- 112 Baum A, Ajithdoss D, Copin R, *et al.* REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. *Science* 2020;370:1110–5.
- 113 Martin PJ, Rizzo JD, Wingard JR, *et al.* First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of blood and marrow transplantation. *Biol Blood Marrow Transplant* 2012;18:1150–63.
- 114 Cooper AS. Corticosteroids for treating sepsis in children and adults. *Crit Care Nurse* 2020;40:83–4.
- 115 Horby P, Lim WS, *et al.* Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* 2020.
- 116 Sterne JAC, Diaz J, Villar J, *et al.* Corticosteroid therapy for critically ill patients with COVID-19: a structured summary of a study protocol for a prospective meta-analysis of randomized trials. *Trials* 2020;21:734.
- 117 Bacigalupo A, Angelucci E, Raiola AM, *et al.* Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab. *Bone Marrow Transplant* 2020;55:1580–7.
- 118 Scott LJ. Tocilizumab: a review in rheumatoid arthritis. *Drugs* 2017;77:1865–79.
- 119 Maude SL, Laetsch TW, Buechner J, *et al.* Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med* 2018;378:439–48.
- 120 Luo P, Liu Y, Qiu L, *et al.* Tocilizumab treatment in COVID-19: a single center experience. *J Med Virol* 2020;92:814–8.
- 121 Xu X, Han M, Li T, *et al.* Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A* 2020;117:10970–5.
- 122 Guaraldi G, Meschiari M, Cozzi-Lepri A, *et al.* Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol* 2020;2:e474–84.
- 123 Stone JH, Frigault MJ, Serling-Boyd NJ, *et al.* Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med Overseas Ed* 2020;383:2333–44.
- 124 Salvarani C, Dolci G, Massari M, *et al.* Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. *JAMA Intern Med* 2021;181:24–31.
- 125 Hermine O, Mariette X, Tharaux P-L, *et al.* Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. *JAMA Intern Med* 2021;181:32.
- 126 Gupta S, Wang W, Hayek SS, *et al.* Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. *JAMA Intern Med* 2021;181:41.
- 127 Rosas IO, Bräu N, Waters M, *et al.* Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. *N Engl J Med* 2021. doi:10.1056/NEJMoa2028700. [Epub ahead of print: 25 Feb 2021].
- 128 Lescuré F-X, Honda H, Fowler RA, *et al.* Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2021. doi:10.1016/S2213-2600(21)00099-0. [Epub ahead of print: 04 Mar 2021].
- 129 Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. *J Clin Oncol* 2012;30:1005–14.
- 130 Campbell PJ, Baxter EJ, Beer PA, *et al.* Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. *Blood* 2006;108:3548–55.
- 131 Zeiser R, von Bubnoff N, Butler J, *et al.* Ruxolitinib for Glucocorticoid-Refractory acute graft-versus-host disease. *N Engl J Med* 2020;382:1800–10.
- 132 La Rosée F, Bremer HC, Gehrke I, *et al.* The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. *Leukemia* 2020;34:1805–15.
- 133 Beigel JH, Tomashek KM, Dodd LE, *et al.* Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020;383:1813–26.
- 134 Kalil AC, Patterson TF, Mehta AK, *et al.* Baricitinib plus Remdesivir for hospitalized adults with Covid-19. *N Engl J Med* 2021;384:795–807.
- 135 Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. *J Rheumatol* 2009;36:1118–25.
- 136 Huet T, Beaussier H, Voisin O, *et al.* Anakinra for severe forms of COVID-19: a cohort study. *Lancet Rheumatol* 2020;2:e393–400.
- 137 Locatelli F, Jordan MB, Allen C, *et al.* Emapalumab in children with primary hemophagocytic lymphohistiocytosis. *N Engl J Med* 2020;382:1811–22.
- 138 Stallmach A, Kortgen A, Gonnert F, *et al.* Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series. *Crit Care* 2020;24:444.
- 139 Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? *Lancet Rheumatol* 2020;2:e779–90.
- 140 Laterre PF, François B, Collienne C, *et al.* Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19). *JAMA Netw Open* 2020;3:e2016485.
- 141 Cairo MS, Cooke KR, Lazarus HM, *et al.* Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. *Br J Haematol* 2020;190:822–36.
- 142 Diurno F, Numis FG, Porta G, *et al.* Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. *Eur Rev Med Pharmacol Sci* 2020;24:4040–7.
- 143 Laurence J, Mulvey JJ, Seshadri M, *et al.* Anti-Complement C5 therapy with eculizumab in three cases of critical COVID-19. *Clin Immunol* 2020;219:108555.
- 144 Mastellos DC, Pires da Silva BGP, Fonseca BAL, *et al.* Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. *Clin Immunol* 2020;220:108598.
- 145 León López R, Fernández SC, Limia Pérez L, *et al.* Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR study): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. *BMJ Open* 2020;10:e039951.
- 146 Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. *Eur J Clin Invest* 2021;51:e13429.
- 147 Jodele S, Davies SM, Lane A, *et al.* Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. *Blood* 2014;124:645–53.
- 148 Leng Z, Zhu R, Hou W, *et al.* Transplantation of ACE2⁺ Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. *Aging Dis* 2020;11:216–28.
- 149 Shang J, Wan Y, Luo C, *et al.* Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A* 2020;117:11727–34.
- 150 Pan J, Yang JF, Deng BP, *et al.* High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. *Leukemia* 2017;31:2587–93.
- 151 Hossain NM, Chapuis AG, Walter RB. T-Cell Receptor-Engineered cells for the treatment of hematologic malignancies. *Curr Hematol Malig Rep* 2016;11:311–7.